Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.50
Ask: 42.50
Change: 1.00 (2.44%)
Spread: 1.00 (2.41%)
Open: 42.25
High: 42.50
Low: 41.00
Prev. Close: 41.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Tern raises GBP6 million; Kromek revenue down

Wed, 14th Jul 2021 11:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Symphony Environmental Technologies, up 11% at 21.17 pence, 12-month range 10.65p-47.0p. The anti-microbial plastic technologies firm receives approval from the US Food & Drug Administration for its d2p antimicrobial food contact technology.

----------

88 Energy, up 7.9% at 1.89p, 12-month range 0.24p-4.70p. The Alaska-focused oil exploration and appraisal company says additional phase one geochemical analysis of fluid extracts from Merlin-1 well core samples again demonstrates the presence of hydrocarbons. Results from phase two of side-wall core trim analysis are expected in the next few weeks. Phase two is designed to confirm not only the presence of oil but also the nature of the source rock, to help understand the likely quality of the oil as well as migration pathways.

----------

Alpha FX Group, up 6.7% at 1,665.00p, 12-month range 677p-1,720p. The foreign exchange risk management and international payments firm says trading in the first half ended June 30 has been "strong" across its business, with revenue up 89% year on year at GBP34 million. Adds 84 new clients and notes average revenue per client continued to increase. The company expects to exceed current internal expectations for 2021, on the back of continued strong trading. In 2020, saw revenue of GBP46.2 million with pretax profit of GBP17.1 million.

----------

Avacta, up 5.9% at 143.56p, 12-month range 88.66p-291.80p. The developer of diagnostics and cancer therapies says Life Sciences unit gets ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.

----------

Fulcrum Utility Services, up 5.6% at 32.74p, 12-month range 28.25p-43.60p. The energy and multi-utility services provider wins new GBP4.9 million multi-utility infrastructure contract from unnamed "large investor developer", for a "major" new employment park in the West Midlands. As part of the contract, the company will design and install a high voltage primary substation and the electricity, water, and gas infrastructure to "energise and power" the new development.

----------

AIM - LOSERS

----------

Tern, down 13% at 19.40p, 12-month range 5.50p-31.67p. The investment firm completes fundraise at the issue price of 18.8p per share. The retail offer and subscription were both oversubscribed and the company said it raised GBP2 million and GBP4 million, respectively. "We intend to utilise the proceeds to maximise the value to our shareholders of our portfolio, and I look forward to providing further updates in due course," says Chief Executive Al Sisto.

----------

Kromek Group, down 7.0% at 15.00p, 12-month range 7.66p-25.20p. The detection technology firm says revenue totalled GBP10.4 million for the financial year that ended April 30 versus GBP13.1 million the year before. Pretax loss, however, narrows to GBP6.3 million from GBP18.3 million loss the year prior. This is due to non-repeat of GBP13.1 million of exceptional impairment losses on trade receivables and amounts recoverable on contracts. Separately, Kromek says it wins new contracts and orders across all segments for delivery this year.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Apr 2019 09:49

Avacta Shares Fall On Widened Interim Loss, Lower Revenue

LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a

Read more
28 Jan 2019 12:01

Avacta Hires IP Group Unit Boss Sam Williams As Non-Executive Director

LONDON (Alliance News) - Avacta Group PLC on Monday said it has appointed Sam Williams as a non-executive director with immediate effect.The biotechnology company said Williams is currently

Read more
21 Jan 2019 12:14

Avacta Group makes solid development progress

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on its trading on Monday, as investors gathered for its annual general meeting.

Read more
3 Jan 2019 11:34

IP Group Builds Over 17% Holding In Biotechnology Firm Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said IP Group PLC now holds 17.2% stake in the biotechnology company following a transaction on December 18.Prior to that, IP holding

Read more
12 Dec 2018 11:14

Avacta Group Appoints Roche's Jose Saro As Chief Medical Officer

LONDON (Alliance News) - Reagents developer Avacta Group PLC on Wednesday appointed Jose Saro as chief medical officer to lead the firm's therapeutic development strategy.Saro brings 20

Read more
12 Dec 2018 09:45

Avacta Group picks up Jose Saro as chief medical officer

(Sharecast News) - Biotherapeutic development company Avacta Group announced on Wednesday that Dr Jose Saro has been appointed as its chief medical officer, to lead its therapeutic development strategy and drive the in-house programmes into the clinic.

Read more
10 Dec 2018 08:52

IP Group Investee Teams With LG Chem To Develop Affimer Drug Candidate

LONDON (Alliance News) - IP Group PLC on Monday said its portfolio company Avacta Group PLC signed a development & license deal with LG Chem Life Sciences.IP Group currently holds a in

Read more
10 Oct 2018 16:33

Avacta 'delighted' at license agreement with longtime collaborator

(Sharecast News) - Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday.

Read more
2 Oct 2018 15:23

Avacta hails progress on in-house and third-party programmes

(Sharecast News) - Avacta Group posted a slightly wider full-year loss on Wednesday even as it highlighted progress both with its in-house programmes and third parties.

Read more
2 Oct 2018 09:42

Avacta Annual Revenue Increases But Loss Widens On Higher Expenses

LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to progress Affimer.The reagents developer a

Read more
23 Aug 2018 17:38

FIL Reduces Avacta Stake To Below 5% Threshold After Deal (ALLISS)

LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction on Tuesday.FIL lowered its holding to a

Read more
23 Aug 2018 14:20

Lombard Odier Asset Management Lowers Holding In Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company.In a transaction on Tuesday, Lombard to

Read more
30 Jul 2018 18:17

UPDATE: Avacta Raises GBP12 Million To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC late Monday said it raised GBP11.6 million before expenses to help fund new drug development partnerships.Early on Monday, to

Read more
30 Jul 2018 12:48

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to help fund new drug development is to place at

Read more
24 Jul 2018 11:26

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, professor of developmental, chemical and molecular Biology at Tufts University School of Medicine in Boston.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.